Augmentin 875 mg/125 mg is a prescription antibiotic tablet containing 875 mg of amoxicillin and 125 mg of clavulanic acid, supplied as clavulanate potassium. The conventional tablet is an immediate-release combination product with two active components. Amoxicillin is a penicillin-class antibacterial, while clavulanate inhibits certain beta-lactamase enzymes that can inactivate susceptible penicillin antibiotics. The complete 875/125 mg designation is essential: this medicine is not the same as plain amoxicillin 875 mg, which contains no clavulanate.
The conventional 875/125 mg tablet has an amoxicillin-to-clavulanic-acid ratio of 7:1. The July 2026 FDA prescribing information identifies the branded presentation as a scored, white, capsule-shaped tablet marked AUGMENTIN 875. It also describes specific brand package configurations. FDA-approved generic products may use different imprints, labelers and packaging, so a pharmacy listing should be evaluated by its complete ingredient strength, dosage form and approved product identity rather than brand recognition alone. The 875/125 mg immediate-release tablet is also distinct from Augmentin XR and Augmentin ES-600, which have different formulation characteristics.
For a U.S. patient with an existing prescription, the practical task is to confirm the intended 875/125 mg combination tablet, distinguish branded and generic presentations, and verify the exact product and quantity the pharmacy can dispense. FDA approval records and published labeling help establish regulatory identity but do not guarantee current pharmacy stock, insurance coverage or clinical suitability. This page focuses on the 875/125 mg strength and its specific identification requirements; the broader Augmentin tablets guide compares the complete conventional tablet family.
The conventional Augmentin 875 mg/125 mg tablet is a fixed-combination oral antibacterial medicine. Each tablet contains 875 mg of amoxicillin, supplied as amoxicillin trihydrate, and 125 mg of clavulanic acid, supplied as clavulanate potassium. The two quantities represent active ingredients within one tablet rather than a total recommended dose or treatment schedule.
The medicine belongs to the immediate-release Augmentin tablet family. The FDA distinguishes this conventional formulation from Augmentin XR extended-release tablets, chewable tablets and powders for oral suspension. Although several products contain the same two active ingredients, their strength pairs, component ratios and dosage-form characteristics differ.
Amoxicillin acts against susceptible bacteria by interfering with bacterial cell-wall synthesis. Clavulanate inhibits certain beta-lactamase enzymes that would otherwise reduce amoxicillin activity. This combination can retain activity against some beta-lactamase-producing organisms, but it does not overcome all bacterial resistance mechanisms or automatically make the medicine preferable to plain amoxicillin.
The 875/125 mg designation is particularly important when reviewing pharmacy catalogs. A product described only as amoxicillin 875 mg is not necessarily an amoxicillin/clavulanate combination. Likewise, a generic product listed under the familiar Augmentin name may be supplied using the established ingredient name rather than the original branded package.
The Augmentin brand guide explains the complete branded product family, while the generic amoxicillin/clavulanate guide addresses approved generic combination products. This page concentrates on the specific 875/125 mg immediate-release tablet without providing personalized strength-selection advice.
The first number in the 875 mg/125 mg strength pair identifies the quantity of amoxicillin. The second identifies the quantity of clavulanic acid supplied as clavulanate potassium. Both quantities matter because amoxicillin and clavulanate are separate active components with different pharmacological functions.
The amoxicillin-to-clavulanic-acid ratio is 875:125, conventionally expressed as 7:1. This ratio identifies the formulation's composition. It does not mean that the product is seven times more effective than another antibiotic, nor does it establish a preferred dose or clinical outcome.
FDA labeling expresses the second component as clavulanic acid even though the pharmaceutical ingredient is supplied as clavulanate potassium. Consequently, a product described as containing 125 mg of clavulanic acid should not be interpreted as containing 125 mg total mass of clavulanate potassium. The acid-equivalent convention supports consistent interpretation of branded and generic strength information.
The 875/125 mg tablet contains the same nominal 125 mg clavulanic-acid quantity as the conventional 250/125 mg and 500/125 mg tablets, but more amoxicillin per tablet. These differences produce distinct component ratios. The tablets cannot be treated as freely interchangeable merely because they share the same clavulanate quantity.
When comparing a prescription, manufacturer label or pharmacy quote, the full product identity should include both ingredient amounts, the conventional immediate-release tablet dosage form and the specific approved product. An abbreviated listing showing only 875 mg requires clarification before it can be treated as a match.
| Product characteristic | FDA-labeled information | Identification significance |
|---|---|---|
| First active component | Amoxicillin 875 mg, supplied as amoxicillin trihydrate | Identifies the penicillin-class antibacterial component. |
| Second active component | Clavulanic acid 125 mg, supplied as clavulanate potassium | Identifies the beta-lactamase inhibitor component. |
| Ingredient proportion | 875:125, equivalent to 7:1 | Distinguishes this strength from conventional 250/125 mg and 500/125 mg tablets. |
| Dosage form | Conventional immediate-release oral tablet | Separates the product from extended-release, chewable and suspension formulations. |
| FDA-described brand appearance | Scored, white, capsule-shaped tablet marked AUGMENTIN 875 | Identifies the specified branded presentation rather than every generic tablet. |
| Prescription status | Prescription-only antibacterial medicine | Requires appropriate clinical prescribing and lawful pharmacy dispensing. |
The July 2026 FDA prescribing information describes branded Augmentin 875 mg/125 mg as a scored, white, capsule-shaped tablet. One side is debossed with AUGMENTIN 875, while the other side has a score. These characteristics differ from the white oval conventional 250/125 mg and 500/125 mg brand tablets, which have separate strength-specific markings.
The branded tablet's imprint identifies its proprietary presentation but does not replace verification of the complete two-component strength. A score line is a physical characteristic of the described tablet. Its presence should not be interpreted as permission to split the tablet or change the prescribed amount without pharmacist or prescriber instructions.
The original branded appearance is not a universal standard for approved generic products. Generic amoxicillin/clavulanate 875/125 mg tablets may have different shapes, colors, coatings, imprints or inactive ingredients under applicable FDA requirements. A difference in appearance does not independently establish inferior quality, incorrect dispensing or lack of approval.
An actual tablet should be identified by reconciling the pharmacy dispensing label, product name, complete strength pair, manufacturer or labeler and relevant official product information. Online pill photographs and historical packaging records may provide context but cannot establish what is inside an individual patient's container.
If the dispensed tablet differs unexpectedly from a previous refill or does not appear to match the pharmacy label, the patient should ask the dispensing pharmacist to verify the medicine before taking an uncertain product. The Augmentin product authenticity guide examines official package and identifier checks in greater detail.
Section 16, Table 19 of the July 2026 FDA prescribing information identifies three branded Augmentin 875 mg/125 mg package configurations: a bottle of 20 tablets, a unit-dose package containing 100 tablets arranged as 10 by 10, and a bottle of 100 tablets. These are FDA-label-specific package records rather than assumptions about current pharmacy inventory.
The corresponding label-listed NDC identifiers are 81964-021-14 for the 20-tablet bottle, 81964-021-78 for the 100-tablet unit-dose configuration and 81964-021-01 for the 100-tablet bottle. These identifiers describe particular labeled product and package configurations. Their inclusion in prescribing information does not prove that each package is currently manufactured, distributed, orderable or stocked by a particular pharmacy.
The same tablet strength can therefore appear in more than one package quantity. When checking a pharmacy quote, the prescribed dispensing quantity should be distinguished from the manufacturer's original package size. A pharmacy may dispense a prescription quantity that differs from an original package configuration, subject to applicable dispensing procedures.
Generic products can carry different NDCs because they may be associated with different labelers, package configurations or repackaging arrangements. A generic 875/125 mg product should not be assigned the original brand NDC merely because the active ingredients and strength pair match. The actual package identifier must correspond to the product being supplied.
NDC information is useful for reconciling drug listings and pharmacy records, but an NDC alone does not establish FDA approval, authenticity, therapeutic equivalence or current inventory. Approval and marketing information should be checked through their appropriate regulatory records, while the dispensing pharmacy confirms the actual supplied product.
For readers comparing branded and generic offerings, the central questions are whether the prescription identifies the intended 875/125 mg tablet, which specific product the pharmacy can dispense and which package or dispensing quantity is relevant. This page does not interpret historical package records as evidence of guaranteed retail supply.
| FDA-labeled brand configuration | NDC | Package quantity | Verification significance |
|---|---|---|---|
| Augmentin 875/125 mg bottle | 81964-021-14 | 20 tablets | Specific branded package identifier in FDA labeling; current pharmacy supply requires confirmation. |
| Augmentin 875/125 mg unit-dose package | 81964-021-78 | 100 tablets, arranged 10 × 10 | Separately identified unit-dose configuration, not a guarantee of retail availability. |
| Augmentin 875/125 mg bottle | 81964-021-01 | 100 tablets | Distinct labeled package size for the same conventional tablet strength. |
Augmentin 875 mg/125 mg and plain amoxicillin 875 mg are distinct prescription medicines. Both contain amoxicillin, but Augmentin also contains 125 mg of clavulanic acid supplied as clavulanate potassium. The shared 875 mg amoxicillin quantity does not establish that the two products have the same composition or can be used interchangeably.
Plain amoxicillin is a single-ingredient penicillin-class antibacterial. Augmentin adds a beta-lactamase inhibitor that may extend activity against certain beta-lactamase-producing bacteria. This difference can matter clinically, but it does not make the combination universally preferable. Antibiotic selection depends on the suspected or confirmed infection, organism susceptibility, patient factors and relevant treatment guidance.
The distinction also affects product search results. A pharmacy listing for amoxicillin 875 mg tablets should not be treated as an equivalent listing for amoxicillin/clavulanate 875/125 mg tablets. The presence or absence of clavulanate changes the medicine's identity, and both active ingredients must be reflected in an accurate combination-product label.
A shortened label or search title that mentions only Augmentin 875 mg should be reconciled with the full ingredient pair before interpreting the listing. Product-name similarity does not eliminate the need to check the actual prescription, dosage form and supplied medicine.
The plain amoxicillin 875 mg product guide covers single-ingredient tablets. Readers seeking the broader clinical and pharmaceutical distinction can consult the Augmentin vs amoxicillin comparison. This strength page does not recommend either product for a particular infection.
| Product | Amoxicillin | Clavulanic acid | Product identity |
|---|---|---|---|
| Augmentin 875/125 mg conventional tablet | 875 mg | 125 mg | Two-ingredient amoxicillin/clavulanate combination. |
| Plain amoxicillin 875 mg tablet | 875 mg | Not present | Single-ingredient amoxicillin product. |
The 875/125 mg product is one of three conventional immediate-release Augmentin tablet strengths described in FDA labeling. The other two are 250/125 mg and 500/125 mg. All three contain 125 mg of clavulanic acid per tablet, but their amoxicillin quantities differ. This means each has a distinct ingredient ratio and a separate strength identity.
The 250/125 mg conventional tablet has a 2:1 amoxicillin-to-clavulanic-acid ratio, while the 500/125 mg tablet has a 4:1 ratio. The 875/125 mg tablet has a 7:1 ratio. These numerical differences are pharmaceutical composition characteristics rather than rankings of clinical effectiveness.
The FDA explicitly prohibits replacing one conventional 500/125 mg tablet with two conventional 250/125 mg tablets because the resulting clavulanate total would be different. This illustrates why tablet quantities cannot be adjusted solely to match the amoxicillin amount. Similar care is required when comparing the 875/125 mg tablet with other strength pairs.
A prescription for the 875/125 mg formulation should not be interpreted as permission to substitute a different conventional tablet strength or combine leftover tablets. The appropriate product depends on the prescription and professional review, not a calculation derived from the first strength number.
The Augmentin 500/125 mg guide and Augmentin 250/125 mg guide address those distinct tablet strengths. For a side-by-side overview of the entire immediate-release tablet family, see the Augmentin tablets comparison.
| Conventional tablet strength | Amoxicillin per tablet | Clavulanic acid per tablet | Component ratio |
|---|---|---|---|
| 250 mg/125 mg | 250 mg | 125 mg | 2:1 |
| 500 mg/125 mg | 500 mg | 125 mg | 4:1 |
| 875 mg/125 mg | 875 mg | 125 mg | 7:1 |
The FDA provides specific guidance for switching between certain conventional Augmentin tablets and other immediate-release dosage forms. Section 2.8, Table 6 identifies the 200 mg/28.5 mg and 400 mg/57 mg suspension or chewable strength families in relation to the conventional 875 mg/125 mg tablet. These formulations share an approximately 7:1 ingredient proportion but are not identical in their per-unit quantities.
The conventional 875/125 mg tablet contains 875 mg of amoxicillin and 125 mg of clavulanic acid in one tablet. By comparison, the 400 mg/57 mg chewable tablet contains 400 mg and 57 mg, respectively, while the corresponding oral suspension expresses these quantities per 5 mL after reconstitution. The 200 mg/28.5 mg products contain smaller quantities with a similar component ratio.
The FDA table identifies formulation families that may be considered during professionally managed changes. It is not a patient-facing instruction to replace one 875/125 mg tablet with a specified number of chewable tablets or a calculated volume of suspension. Differences in concentration, dosage form, prescription requirements and patient population must be evaluated.
The FDA specifically restricts chewable-tablet substitution to pediatric patients weighing less than 40 kg. Conventional tablets, by contrast, have their own population and swallowing-ability requirements. These distinctions reinforce that a similar ingredient ratio does not establish unrestricted substitution across patient groups.
Oral suspensions also require concentration-based identification and appropriate preparation. A product labeled 400 mg/57 mg per 5 mL is not a ready-made liquid equivalent of one conventional 875/125 mg tablet. The pharmacy must determine the correct prescribed product and provide applicable preparation and administration instructions.
The Augmentin oral suspension guide examines liquid strengths and pharmacy identification, while the Augmentin chewable tablets guide addresses chewable formulations. Neither category should be used for self-directed replacement of a prescription tablet.
| FDA-labeled presentation | Amoxicillin content | Clavulanic acid content | Formulation distinction |
|---|---|---|---|
| 875/125 mg conventional tablet | 875 mg per tablet | 125 mg per tablet | Immediate-release tablet addressed by this page. |
| 200/28.5 mg chewable tablet | 200 mg per chewable tablet | 28.5 mg per chewable tablet | Corresponding strength family in FDA Table 6; subject to pediatric substitution restrictions. |
| 200/28.5 mg per 5 mL oral suspension | 200 mg per 5 mL | 28.5 mg per 5 mL | Liquid strength family identified in FDA Table 6. |
| 400/57 mg chewable tablet | 400 mg per chewable tablet | 57 mg per chewable tablet | Corresponding strength family in FDA Table 6; not a one-unit tablet replacement. |
| 400/57 mg per 5 mL oral suspension | 400 mg per 5 mL | 57 mg per 5 mL | Liquid strength family identified in FDA Table 6. |
The conventional 875 mg/125 mg tablet must be distinguished from related Augmentin formulations that use different release technologies or component concentrations. Augmentin XR is a separately labeled extended-release tablet, while Augmentin ES-600 is a specialized oral suspension. Both contain amoxicillin and clavulanate, but they are not alternative package descriptions for the conventional 875/125 mg tablet.
Augmentin XR contains 1,000 mg of amoxicillin and 62.5 mg of clavulanic acid per extended-release tablet. Its pharmaceutical design provides extended amoxicillin exposure compared with conventional immediate-release formulations. The FDA warns against assuming equivalence based on amoxicillin totals, including an explicit restriction involving two conventional 500 mg tablets and one XR 1,000 mg tablet.
The conventional 875/125 mg tablet and the XR 1,000/62.5 mg tablet differ in both active-component quantities and release characteristics. The presence of a score line on either product does not eliminate those differences or justify splitting, combining or exchanging tablets independently.
Augmentin ES-600 contains 600 mg of amoxicillin and 42.9 mg of clavulanic acid per 5 mL after reconstitution. It is a distinct pediatric oral suspension with its own labeling. It should not be interpreted as a concentrated liquid replacement for the 875/125 mg conventional tablet.
The Augmentin XR guide and Augmentin ES-600 guide cover those products in detail. This page remains limited to identifying the conventional 875/125 mg immediate-release tablet and preventing confusion with separately labeled formulations.
Generic amoxicillin/clavulanate 875 mg/125 mg tablets may be approved through the FDA's Abbreviated New Drug Application pathway. An independently approved generic must satisfy applicable requirements related to its reference product, including pharmaceutical equivalence, bioequivalence and quality standards. The approval applies to a specific drug product, dosage form and strength rather than every medicine containing the same ingredient names.
The FDA Orange Book provides approved-product and applicable therapeutic-equivalence information. When evaluating a generic 875/125 mg tablet, the relevant regulatory comparison includes its application, reference relationship, dosage form and complete strength pair. A therapeutic-equivalence determination for a particular product does not establish interchangeability with XR, ES-600 or unrelated concentrations.
The branded tablet described in FDA labeling has an AUGMENTIN 875 imprint and specific physical characteristics. Approved generic products may look different and may be supplied under other manufacturer or labeler names. Different appearances and inactive ingredients can be permitted under FDA requirements, provided the applicable approval standards are satisfied.
An authorized generic differs from an independently approved ANDA generic because it is marketed without the brand name under the brand product's approved NDA. The phrase generic Augmentin does not establish which regulatory category a particular pharmacy product belongs to. Product-specific records are necessary for that distinction.
Published NDCs and labeler information can help identify an actual package, but the entity listed on a package may be a distributor or repackager rather than the original application holder. FDA approval status, commercial marketing and present pharmacy availability are separate questions that should not be combined into a single assumption.
For broader regulatory details, consult the FDA-approved Augmentin products guide. The generic amoxicillin/clavulanate manufacturers directory addresses applicant and labeler identities separately. This strength page does not attempt to maintain a complete manufacturer catalog.
A legitimate U.S. pharmacy transaction for Augmentin 875/125 mg requires a valid prescription and appropriate dispensing review. The product-verification process begins by confirming that the prescribed medicine is the two-ingredient amoxicillin/clavulanate combination and that the specified dosage form is a conventional immediate-release tablet.
The complete strength pair is essential. The pharmacy should confirm 875 mg of amoxicillin and 125 mg of clavulanic acid, rather than relying on the shortened expression Augmentin 875 or amoxicillin 875. A plain-amoxicillin listing, an XR product or a different combination strength does not automatically represent the intended prescription.
When both brand and generic products appear in a pharmacy catalog, the actual dispensed product should be distinguished from the product name used in a search result. Any generic substitution must comply with applicable therapeutic-equivalence information, prescription restrictions and state pharmacy requirements.
The pharmacy can confirm the manufacturer or labeler, NDC where applicable, dosage form and dispensed quantity. Package-specific information may differ between the original branded product, independently approved generics and repackaged medicines. A published FDA or DailyMed record does not guarantee that a particular product is currently stocked.
A useful verification step is to reconcile the pharmacy quotation with the intended tablet strength and actual quantity being dispensed. A 20-tablet branded package, a 100-tablet unit-dose package and a generic prescription quantity are not automatically equivalent commercial offers even when the active-component strength is identical.
If the intended product is unavailable, the pharmacist should explain what legally and clinically appropriate options may exist and whether prescriber authorization is required. Patients should not change strengths, split tablets or substitute a liquid formulation independently.
The Augmentin online pharmacy guide explains how to assess prescription-based dispensing services, while the Augmentin online prescription guide addresses clinical evaluation before a prescription is issued. This page concentrates on verifying an existing prescription.
| Verification item | What to confirm | Why it matters |
|---|---|---|
| Active ingredients | Amoxicillin and clavulanate potassium | Separates the combination from plain amoxicillin 875 mg. |
| Exact strength | 875 mg amoxicillin / 125 mg clavulanic acid | Both active-component quantities define the product. |
| Dosage form | Conventional immediate-release tablet | Distinguishes the medicine from XR, chewable and liquid formulations. |
| Brand or generic | Actual dispensed product and relevant FDA approval identity | A brand-name catalog heading may describe a generic product. |
| Manufacturer or labeler | Company information on the actual supplied package | Helps reconcile the product with published labeling. |
| NDC | Product and package identifier when available | Supports identification without independently proving approval or stock. |
| Dispensed quantity | Quantity authorized and supplied under the prescription | Prevents confusion between original package configurations and the actual fill. |
| Substitution status | Prescription restrictions and applicable therapeutic-equivalence rules | Prevents assumptions about unrestricted changes. |
The conventional Augmentin 875/125 mg tablet contains a penicillin-class antibacterial and is subject to the contraindications and warnings in the applicable FDA-approved labeling. A history of serious hypersensitivity reactions to Augmentin or other beta-lactam antibacterial drugs is a major contraindication. Previous Augmentin-associated cholestatic jaundice or hepatic dysfunction is also identified as a contraindication.
Potential adverse reactions include diarrhea, nausea, vomiting and skin reactions. The prescribing information also identifies serious risks such as anaphylaxis, severe cutaneous adverse reactions, liver injury and Clostridioides difficile-associated diarrhea. Sudden breathing difficulty, throat swelling or other signs of a severe allergic reaction require emergency medical attention.
The FDA labeling describes interactions and precautions involving medications such as probenecid, oral anticoagulants and allopurinol. Kidney function, medication history, previous antibiotic reactions and other clinical characteristics may affect professional treatment decisions. The 875/125 mg strength designation does not provide enough information to determine an appropriate regimen for an individual patient.
The 7:1 component ratio is important for product identification but should not be interpreted as a measure of safety or comparative therapeutic superiority. A different strength or dosage form may change exposure to one or both active components. Patients should not alter the prescribed tablet quantity, administration schedule or formulation independently.
Responsible antibacterial use requires an appropriate indication and adherence to the instructions provided by the prescriber. Patients should not take leftover Augmentin tablets for a new illness or share antibiotics with another person. Augmentin does not treat viral infections such as influenza or the common cold, and unnecessary use can contribute to antibiotic resistance.
For additional information about reported beta-lactam hypersensitivity, see the penicillin allergy guide. This page provides product-identification and general safety information rather than individualized medical advice.
The cost of Augmentin 875/125 mg depends on the product actually dispensed, the prescription quantity, the pharmacy and any applicable insurance or discount arrangements. Brand-name and generic tablets may have different pricing. However, no particular product category guarantees the lowest out-of-pocket cost in every transaction.
Package quantity is an important comparison variable. The July 2026 FDA label identifies branded 875/125 mg configurations containing 20 or 100 tablets. A pharmacy quote for a different dispensed quantity should not be interpreted as the price of one of those original packages unless the pharmacy confirms the specific product and terms.
Generic products can carry different NDCs and may come from different applicants, labelers or repackagers. Consequently, a price listing for one generic package does not automatically describe another product with the same active-component strength. The actual approved and dispensed product should be established before comparing quotations.
Published FDA approval records and package descriptions do not establish current retail distribution or local inventory. A particular pharmacy may be able to supply an approved generic but not a specified branded package, or vice versa. Any permitted alternative must remain consistent with the prescription and professional dispensing requirements.
The Augmentin brand price guide covers branded cost considerations, while the generic amoxicillin/clavulanate price guide addresses generic cash-price comparisons. Questions about formulary treatment belong in the Augmentin insurance coverage guide.
This page does not provide unverified retail offers, assumed discount eligibility, guaranteed insurance benefits or promises about stock and delivery. Its purpose is to ensure that any future cost comparison refers to the correct 875/125 mg product and dispensing quantity.
Augmentin 875/125 mg is a prescription combination antibiotic tablet containing 875 mg of amoxicillin and 125 mg of clavulanic acid, supplied as clavulanate potassium. The conventional tablet is an immediate-release product and is distinct from plain amoxicillin 875 mg.
The first number identifies 875 mg of amoxicillin, while the second identifies 125 mg of clavulanic acid. Both quantities are present in one conventional tablet. The complete strength pair is necessary to distinguish the combination from other antibiotics and Augmentin formulations.
No. Plain amoxicillin 875 mg contains amoxicillin without clavulanate. Augmentin 875/125 mg contains two active ingredients: amoxicillin and clavulanate potassium. The medicines have different compositions and should not be exchanged without professional assessment.
The tablet contains 875 mg of amoxicillin and 125 mg of clavulanic acid, giving a 7:1 amoxicillin-to-clavulanic-acid ratio. This is a description of the product's composition rather than a measure of comparative clinical effectiveness.
The July 2026 FDA prescribing information describes the branded tablet as white, capsule-shaped and scored. It is debossed with AUGMENTIN 875 on one side and has a score on the other. Approved generic tablets may have different appearances and imprints.
The FDA describes the branded tablet as scored, but the presence of a score does not by itself establish that splitting is appropriate for a particular prescription. Patients should follow their prescribed instructions and ask a pharmacist before changing how the tablet is administered.
The conventional Augmentin 875/125 mg tablet is an immediate-release formulation. Augmentin XR is a separate extended-release product containing 1,000 mg of amoxicillin and 62.5 mg of clavulanic acid per tablet. They are not interchangeable based solely on their shared active ingredients.
The July 2026 FDA prescribing information lists branded configurations containing 20 tablets in a bottle, 100 tablets in unit-dose packaging and 100 tablets in a bottle. These regulatory package descriptions do not establish whether a particular configuration is currently stocked by a pharmacy.
The July 2026 FDA label lists 81964-021-14 for a 20-tablet bottle, 81964-021-78 for a 100-tablet unit-dose package and 81964-021-01 for a 100-tablet bottle. These identifiers do not independently guarantee current commercial distribution or pharmacy inventory.
An appropriately FDA-approved generic may be therapeutically equivalent to its corresponding branded reference product when the applicable requirements are satisfied. The complete strength pair, dosage form, approval relationship and relevant substitution rules must be checked. Generic tablets may differ in appearance and packaging.
Yes. FDA-approved generic products can differ from the branded reference product in imprint, shape, color, inactive ingredients and packaging within applicable regulatory requirements. The actual dispensed tablet should be verified against its product labeling and pharmacy record.
Both conventional tablet strengths contain 125 mg of clavulanic acid, but the 875/125 mg tablet contains 875 mg of amoxicillin compared with 500 mg in the 500/125 mg tablet. They have different ingredient ratios and are not freely interchangeable.
No automatic interchangeability should be assumed. Augmentin XR has different active-component strengths and extended-release characteristics. The conventional 875/125 mg immediate-release tablet must be distinguished from XR, and any product change requires professional evaluation.
No. Augmentin ES-600 is a specialized oral suspension containing 600 mg of amoxicillin and 42.9 mg of clavulanic acid per 5 mL after reconstitution. It has different concentration, dosage-form and labeling characteristics from the conventional 875/125 mg tablet.
FDA Table 6 identifies the 200/28.5 mg and 400/57 mg oral suspension strength families for consideration when professionally switching from the conventional 875/125 mg tablet. This does not provide a patient-directed liquid dose or authorize independent substitution. The prescriber or pharmacist must evaluate the applicable requirements.
A single 400/57 mg chewable tablet does not contain the same quantities of active ingredients as one 875/125 mg conventional tablet. FDA Table 6 identifies the 400/57 mg strength family in its formulation-switching guidance, subject to professional review and pediatric substitution restrictions. Patients should not calculate replacements independently.
No. Augmentin 875/125 mg is a prescription-only antibiotic in the United States. Lawful dispensing requires a valid prescription and compliance with applicable pharmacy requirements. Online product listings do not establish prescription-free access or guaranteed approval.
Confirm both active ingredients, the complete 875 mg/125 mg strength pair, conventional tablet dosage form, actual brand or generic identity and dispensed quantity. Ask the pharmacist to verify the manufacturer or labeler and NDC where applicable.
No. FDA approval, published labeling and NDC records establish different aspects of regulatory and product identity. They do not guarantee current commercial distribution or local pharmacy stock. The pharmacy must confirm the particular product and quantity it can dispense.
No. Clavulanate can extend antibacterial activity against certain beta-lactamase-producing organisms, but the combination is not universally preferable. Antibiotic selection depends on the infection, suspected or confirmed pathogens, susceptibility and patient-specific considerations.
Augmentin contains amoxicillin, a penicillin-class antibacterial. Its FDA labeling contraindicates use in patients with a history of serious hypersensitivity reactions to Augmentin or other beta-lactam antibacterial drugs. A reported allergy should be evaluated by a healthcare professional before prescribing.
No. Leftover antibiotics should not be used for self-treatment. A new illness may be caused by a virus or bacteria requiring different management. Unnecessary antibiotic use can cause adverse reactions and contribute to antimicrobial resistance.